Vendor Survival Index
Tracking the US research peptide market through the FDA enforcement cycle.

Vendor Survival Index

Independent editorial. No affiliate commissions. No paid placements.

Editor: Marcus R. Holloway, Regulatory Affairs Analyst

Marcus R. Holloway is a regulatory affairs analyst with a background in FDA enforcement cycles and grey-market supply chain dynamics. Vendor Survival Index was established in 2024 to track compliance posture, operational continuity, and documentation standards among US-accessible research peptide vendors through the post-2024 FDA enforcement period. No affiliate commissions are accepted. No vendors have paid for placement or coverage.

The inaugural analysis from Vendor Survival Index is now available:

Post Fda Peptide Vendor Migration 2026